CELULARITY INC
NASDAQ: CELU (Celularity Inc.)
Last update: yesterday, 2:16AM1.22
-0.05 (-3.94%)
| Previous Close | 1.27 |
| Open | 1.25 |
| Volume | 158,183 |
| Avg. Volume (3M) | 170,536 |
| Market Cap | 35,182,104 |
| Price / Sales | 1.05 |
| Price / Book | 9.89 |
| 52 Weeks Range |
| Profit Margin | -106.77% |
| Operating Margin (TTM) | -52.24% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 49.70% |
| Quarterly Earnings Growth (YOY) | -60.90% |
| Total Debt/Equity (MRQ) | 778.95% |
| Current Ratio (MRQ) | 0.380 |
| Operating Cash Flow (TTM) | -6.40 M |
| Levered Free Cash Flow (TTM) | 10.32 M |
| Return on Assets (TTM) | -17.42% |
| Return on Equity (TTM) | -232.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Celularity Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 51.26% |
| % Held by Institutions | 14.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| C V Starr & Co Inc | 31 Dec 2025 | 764,069 |
| Valmark Advisers, Inc. | 31 Dec 2025 | 49,983 |
| Hb Wealth Management, Llc | 31 Dec 2025 | 40,415 |
| Biltmore Family Office, Llc | 31 Dec 2025 | 35,000 |
| Keynote Financial Services Llc | 31 Dec 2025 | 25,320 |
| Ipg Investment Advisors Llc | 31 Dec 2025 | 17,169 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Dec 2025 | Announcement | Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations |
| 22 Dec 2025 | Announcement | Celularity Announces Closing of Financing Transactions |
| 18 Dec 2025 | Announcement | Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |